Form 4 for ENTA ENANTA PHARMACEUTICALS INC
Accepted 2022-12-16 00:00:00 ET · period of report 2022-12-16 · accession 0001062993-22-024037 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2022-12-16 | 2022-12-16 | ENTA | Luly Jay R. | Pres, CEO, Dir | S - Sale+OE | $44.72 | -30.0K | 773.8K | -4% | -$1.34M |
| DM | 2022-12-16 | 2022-12-16 | ENTA | Luly Jay R. | Pres, CEO, Dir | M - OptEx | $14.10 | +30.0K | 790.0K | +4% | +$422.9K |
| DM | 2022-12-16 | 2022-12-16 | ENTA | Luly Jay R. | Pres, CEO, Dir | M - OptEx | $0.00 | -30.0K | 27.9K | -52% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-12-16 | S | D | 8,597 | $44.54 | 787,408 | D | — | — | (F3) The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $44.04 to $44.93, inclusive. |
| 2 | Common | Common Stock | 2022-12-16 | M | A | 13,851 | $14.00 | 803,805 | D | — | — | |
| 3 | Common | Common Stock | 2022-12-16 | S | D | 7,800 | $43.59 | 796,005 | D | — | — | (F2) The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $43.29 to $43.99, inclusive. |
| 4 | Common | Common Stock | 2022-12-16 | M | A | 16,149 | $14.18 | 789,954 | D | — | — | |
| 5 | Common | Common Stock | 2022-12-16 | S | D | 13,603 | $45.49 | 773,805 | D | — | — | (F4) The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.85, inclusive. |
| 6 | Derivative | Stock Option (Right to Buy) | 2022-12-16 | M | D | 16,149 | $0.00 | 0 | D | $14.18 · — to 2022-12-26 | 16,149 Common Stock | (F5) 100% of the shares subject to the option are fully vested and exercisable. |
| 7 | Derivative | Stock Option (Right to Buy) | 2022-12-16 | M | D | 13,851 | $0.00 | 27,912 | D | $14.00 · — to 2023-03-21 | 13,851 Common Stock | (F6) On March 21, 2013, the reporting person was granted an option to purchase 83,526 shares of common stock, which becomes reportable on Form 4 only if and to the extent that the option becomes exercisable. The option becomes exercisable in up to nine installments, based on Enanta's achievement of certain clinical milestones with respect to three or more programs that progress in clinical development. As of the date of this filing, a total of 50% of the shares subject to the option have become exercisable. |